Clinical trial · Interventional
Role of Propranolol as Compared to Bleomycin in Management of Hemangioma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Infantile hemangiomas are widespread vascular tumours having incidence of 10% and most of them involute spontaneously. However, they are known to be located in proximity of vital organs and can have poor cosmetic and functional sequel if left untreated. A wide range of treatment options are available from expectant therapy to radical surgical excision. Propanolol has also been shown to be effective in treating infantile cutaneous hemangiomas. Similarly, anti-metabolite drugs as bleomycin has also shown promising results. Efficacy in terms of reduction in size of both treatments has been scarcely studied especially in Pakistan. OBJECTIVE: To assess the efficacy of oral propranolol and intraleisonal bleomycin in the treatment of infantile cutaneous hemangioma in terms of size regression
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hemangioma | Hemangioma | ONTOLOGY_EXACT | 0.98 |
| Propranolol | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bleomycin | Drug | Bleomycin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Propranolol
- description
- propranolol with a mean dose of 2mg/kg/day in 2 divided doses for a period of 6 months
- interventionNames
- Drug: Bleomycin
- type
- EXPERIMENTAL
- label
- Bleomycin
- description
- Bleomycin 15mg diluted in 15 ml of Normal Saline along with a dosage of 0.5 mg/kg for a period of 6 months.
- interventionNames
- Drug: Bleomycin
Primary outcomes (2)
- measure
- Size change
- timeFrame
- 02 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Months
- Maximum age
- 12 Months
Show eligibility criteria text
Inclusion Criteria: * 1\. 6 month to 12 yr. of age presenting with infantile hemangioma anywhere on body 2. Both sex included 3. Previously not treated Exclusion Criteria: On the basis of history and clinical assessment; 1. Patients with previous treatment of hemangioma. 2. Patients who will be lost to follow up 3. Patients who refused to be enrolled in this study 4. Patients who experienced hypersensitivity to propranolol/Bleomycin during treatment or had previous known allergy to the drugs. 5. Patients who had diagnosed Cardiac disease such as heart failure or AV block. 6. Patients with diagnosed Pulmonary disease such as asthma or bronchiolitis. 7. History of impaired renal or liver functions. 8. Diabetes mellitus \-
References
Publications (1)
- RESULTThayal PK, Bhandari PS, Sarin YK. Comparison of efficacy of intralesional bleomycin and oral propanolol in management of hemangiomas. Plast Reconstr Surg. 2012 Apr;129(4):733e-735e. doi: 10.1097/PRS.0b013e318245e739. No abstract available. PMID 22456397